A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Development of a Refined Protocol for Trans-scleral Subretinal Transplantation of Human Retinal Pigment Epithelial Cells into Rat Eyes

9.3K views

⸱

DOI:

10.3791/55220

⸱

August 12th, 2017

 ,  ,  ,  ,  ,  , 

* These authors contributed equally

In This Article

Summary

Subretinal injection has been widely applied in preclinical studies of stem cell replacement therapy for age-related macular degeneration. In this visualized article, we describe a less risky, reproducible and precisely modified subretinal injection technique via the trans-scleral approach to deliver cells into rat eyes.

Abstract

Degenerative retinal diseases such as age-related macular degeneration (AMD) are the leading cause of irreversible vision loss worldwide. AMD is characterized by the degeneration of retinal pigment epithelial (RPE) cells, which are a monolayer of cells functionally supporting and anatomically wrapping around the neural retina. Current pharmacological treatments for the non-neovascular AMD (dry AMD) only slow down the disease progression but cannot restore vision, necessitating studies aimed at identifying novel therapeutic strategies. Replacing the degenerative RPE cells with healthy cells holds promise to treat dry AMD in the future. Extensive preclinical studies of stem cell replacement therapies for AMD involve the transplantation of stem cell-derived RPE cells into the subretinal space of animal models, in which the subretinal injection technique is applied. The approach most frequently used in these preclinical animal studies is through the trans-scleral route, which is made difficult by the lack of direct visualization of the needle end and can often result in retinal damage. An alternative approach through the vitreous allows for direct observation of the needle end position, but it carries a high risk of surgical traumas as more eye tissues are disturbed. We have developed a less risky and reproducible modified trans-scleral injection method that uses defined needle angles and depths to successfully and consistently deliver RPE cells into the rat subretinal space and avoid excessive retinal damage. Cells delivered in this manner have been previously demonstrated to be efficacious in the Royal College of Surgeons (RCS) rat for at least 2 months. This technique can be used not only for cell transplantation but also for delivery of small molecules or gene therapies.

Introduction

The human retina located at the back of the eye functions as a light sensory tissue and plays a critical role in vision perception. Retinal cell dysfunction or cell death therefore causes vision problems or permanent blindness. Disorders involving degeneration or dysfunction of cells in different layers of the retina are known as degenerative retinal diseases, among which AMD is the most common type and the leading cause of irreversible blindness in the elderly in developed countries1,2. The pathological process of AMD is associated with "drusen" accumulation between the RPE layer and the underlying Br....

Access restricted. Please log in or start a trial to view this content.

Protocol

All procedures involving animals have been approved by the Institutional Animal Care and Use Committee (IACUC) at the State University of New York at Albany.

1. Pre-injection Preparation

  1. Preparation of a hRPESC-RPE cell suspension
    NOTE: All the following steps are performed in sterile tissue culture hood and familiarity with basic sterile technique is required.
    1. Isolate primary hRPE cells from human donor eyes aged 50-90 years and culture cells in 24-well plates12. Cryopreserve the cells at passage 1, thaw as needed and culture passage 2 (P2) cells for 4-5 weeks (

Access restricted. Please log in or start a trial to view this content.

Results

Using the technique described in this article, we consistently delivered hRPESC-RPE cells into the subretinal space of RCS rats by precisely controlling the location, angle, and depth of the injector needle inserting into the tissue (Figure 1B-D). Immediately following transplantation, an OCT examination was performed to observe the injection site and the subretinal bleb created by the transplanted cells. Post-surgical OCT evaluation serves as a screening.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The subretinal injection technique depicted in this article is via the trans-scleral pathway, where the injector needle penetrates the outer layers (sclera-choroid-RPE complex) of the eye wall without harming the neural retina or disturbing the vitreous cavity. An alternative trans-vitreal approach has a potential risk of lens damage leading to cataract, since rodents' lens occupies the majority of the vitreous cavity. Compared to this method, our technique is less risky and causes minimal trauma as the injector need.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

We wish to thank Patty Lederman for her assistance on the surgery and Susan Borden for RPE cell preparation. We also acknowledge NYSTEM C028504 for the funding for this project. Justine D. Miller is supported by NIH grant F32EY025931.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
0.25% Trypsin-EDTA (1x)Life Technologies25200-072
DNAse ISigmaDN-25
1xDulbecco’s Phosphate Buffered Saline without Calcium & Magnesium (1xDPBS-CMF)Corning Cellgro431219
Sterile Balanced Salt Solution (BSS)Alcon00065079550
Sterile eye washMoore Medical75519
Sterile 0.9% salineHospira488810
Proparacaine Hydrochloride Ophthalmic Solution (0.5%)Akorn17478026312
Tropicamide Ophthalmic Solution, USP (1%)Bausch & Lomb24208058559
Phenylepherine Ophtalmic Solution, USP (10%) stockBausch & Lomb42702010305This is used to make 2.5% Phenylepherine
BuprenexPatterson433502
DexamethasoneAPP Pharmaceuticals63323051610
100% EthanolThermo Scientific615090040
70% EthanolRicca Chemical Company2546.70-5
Sterile GenTeal Lubricant Eye GelNovartis78042947
Sterile Systane Ultra Lubricant Eye DropsAlcon00065143105
hRPESC-RPE cellsNot available commerciallyPlease refer to "Reference #12" for cell isolation and mainteinance.
24-well platesCorning3526
Conical tubes (15 ml)Sarstedt62554002
Microcentrifuge cap with o-ringLPS incL233126
Capless Microcentrifuge tubes (1.7 ml)LPS incL233041
CentrifugeEppendorf5804R
Sterile alcohol wipeMcKesson58-204
Sterile cotton tip applicatorsMcKesson24-106-2S
Sterile Weck-Cel spearsBeaver-Visitec International 0008680
Sterile surgical drapes McKesson25-515
GauzeMcKesson16-4242
Nanofil syringe (10 ul)World Precision InstrumentsNanofil
Nanofil beveled 33-gauge needleWorld Precision InstrumentsNF33BV-2
Insulin syringe needles 31-gaugeBecton Dickinson328418
Rat toothed forcepsWorld Precision Instruments555041FT
Vannas Micro Dissecting Spring ScissorsRobozRS-5602
Circulating water T pump StrykerTP700
Heating padKent ScientificTPZ-814
Animal anesthesia systemWorld Precision InstrumentsEZ-7000
BalanceOhausPA1502
Stereo microscopeZeissStemi 2000
Microscope light sourceSchottACE series
Bioptigen Envisu Spectral Domain Ophthalmic Imaging SystemBioptigenR2210
Sterile black marker penViscot Industries1416S-100
Miniature measuring scaleTed Pella Inc13623
Infrared Basking Spot Lamp EXO-TERRAPT2144This is used as a heating lamp for animals during the post-surgical recovery  phase

References

  1. De Jong, P. T. Age-related macular degeneration. N Engl J Med. 355, 1474-1485 (2006).
  2. Wong, W. L., et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic revi....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Trans-scleral Subretinal InjectionHuman RPE CellsRat Subretinal SpaceSclera Penetration TechniquePilot Hole CreationNeedle Angle DepthOptical Coherence TomographyCell Transplantation MethodMinimal Retinal Damage